Health Care/Hospital

BGM Group Ltd Pioneers Innovation in AI Technology, Fostering Holistic Integration of Healthcare and Insurtech

CHENGDU, China, Nov. 29, 2024 /PRNewswire/ -- BGM Group Ltd. (NASDAQ: BGM) ("the Company" or "BGM"), a leading global pharmaceutical enterprise, today announced its acquisition of the intelligent platform of AIX Inc. (NASDAQ: AIFU) ("AIX") valued at1 billion RMB (approximately $140 million). The ...

2024-11-29 23:58 4694

AIX Inc. (NASDAQ:AIFU): Reshaping AI Insurance and the Healthcare Industry--A Promising Future Ahead?

HONG KONG, Nov. 29, 2024 /PRNewswire/ -- AIX Inc. (NASDAQ:AIFU) is a leading company focused on insurance agency and claims services. Recently, the company has been gradually pushing for an intelligent and diversified transformation, aiming to capture growth opportunities in the AI insurance and ...

2024-11-29 23:11 4387

MicuRx: Successfully Completes Phase III Clinical Trial of MRX-4 for Injection in China

SHANGHAI, Nov. 29, 2024 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", 688373.SH) announced the successful completion of its Phase III clinical trial of MRX-4 for injection transitioning to oral Contezolid tablets for the treatment of adult patients with complex sk...

2024-11-29 22:00 2489

What does Taiwan mean to China?

BEIJING, Nov. 29, 2024 /PRNewswire/ -- A news report from China.org.cn:   What does Taiwan mean to China? The Taiwan issue is of great significance and encompasses multiple dimensions, thus it is regarded as a focus of China-U.S. competition. Why is the Taiwan issue the first...

2024-11-29 22:00 2939

Minghui Pharmaceutical Announces Positive Topline Results from Phase Ⅲ Trial of MH004 (Tofacitinib Etocomil) Ointment in Mild to Moderate Atopic Dermatitis

SHANGHAI, Nov. 29, 2024 /PRNewswire/ -- Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative medicines in immunology and oncology, today announced positive topline results from its phase Ⅲ trial of MH004 (tofacitinib etocomil) ointment 1.0%, a twic...

2024-11-29 20:31 2669

Akeso to Present at Citi 2024 Global Healthcare Conference and the 7th Annual Evercore HealthCONx Conference

HONG KONG, Nov. 28, 2024 /PRNewswire/ --  Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce its participation in the upcoming 7th Annual Evercore HealthCONx Conference and Citi 2024 Global Healthcare Conference, both taking place inMiami. Akeso will participate in a firesid...

2024-11-29 10:23 1256

Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline

The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion. SHANGHAI, Nov. 28, 2024 /PRNewswire/ -- Allink Biotherapeutics, a clinical-stage biotechnology company pioneering next-generation bispecifi...

2024-11-28 21:06 2554

Global Times: Atoms for a better home: CNNC showcases 'Chinese solution' on nuclear technology application to the world

VIENNA, Nov. 28, 2024 /PRNewswire/ -- The 2024 International Atomic Energy Agency (IAEA) Ministerial Conference is taking place fromNovember 26 to 28 in Vienna, Austria. On November 26, China held a side event themed "Atoms for a Better Home," focusing on integrated solutions for irradiation and ...

2024-11-28 17:04 1147

Akeso Announced the Inclusion in China's National Reimbursement Drug List of Cadonilimab and Ivonescimab

HONG KONG, Nov. 27, 2024 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce that two of its independently developed, globally pioneering bispecific antibody drugs—cadonilimab Injection (PD-1/CTLA-4 bispecific antibody) and ivonescimab Injection (PD-1/VEGF bi...

2024-11-28 11:58 1743

Lunit Inks Partnership with Salud Digna to Advance AI in Medical Imaging

* AI-powered chest X-ray and mammography analysis solutions to be deployed across one ofMexico's largest healthcare networks SEOUL, South Korea, Nov. 27, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announc...

2024-11-27 22:00 1575

Award-Winning CMUH (Taiwan) Excels at HIMSS, Leading Taiwan's Smart Healthcare Transformation

TAICHUNG, Nov. 27, 2024 /PRNewswire/ -- In HIMSS24 APAC Seoul, Healthcare Conference & Exhibition, China Medical University Hospital (CMUH) established international presence with four notable gradings: achieving the top score in the 2023 HIMSS Global Digital Health Indicator (DHI) and receiving ...

2024-11-27 21:00 1485

Waterdrop Inc. to Report Third Quarter 2024 Financial Results on December 11, 2024

BEIJING, Nov. 27, 2024 /PRNewswire/ -- Waterdrop Inc. (NYSE: WDH ) ("Waterdrop" or the "Company"), a leading technology platform d...

2024-11-27 18:00 1525

111, Inc. Announces Third Quarter 2024 Unaudited Financial Results

* Maintained Operational Profitability for the Third Consecutive Quarter * Operating Expenses as a Percentage of Revenues Decreased 160 Basis Points YoY * Held Positive Operating Cash Flow for Three Consecutive Quarters SHANGHAI, Nov. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company...

2024-11-27 14:00 1542

VectorBuilder and Sartorius Sign Strategic Cooperation Agreement to Advance Biopharmaceutical Innovation

GUANGZHOU, China, Nov. 26, 2024 /PRNewswire/ -- VectorBuilder, a global leader in end-to-end gene delivery services, and Sartorius, a leading international partner in life science research and the biopharmaceutical industry, recently announced a strategic cooperation agreement. The collaboration ...

2024-11-26 22:00 1825

Hankyung.com introduces: ES Technology, the only domestic manufacturer of electric lift, increase the efficiency of specialized equipment such as medical devices and cooperative robots

SEOUL, South Korea, Nov. 26, 2024 /PRNewswire/ -- It is a company that presents ergonomic systems to the industry with the vision of "a company that pursues a convenient life for mankind through automation." Based on more than 24 years of accumulated experience and know-how, it is the only electr...

2024-11-26 21:00 1698

GC Biopharma and Novel Pharma First Patient Dosed in Global Phase I Clinical Trial for MPS IIIA Treatment

YONGIN, South Korea, Nov. 25, 2024 /PRNewswire/ -- GC Biopharma and Novel Pharma today announced that the first patient in the US has been dosed in multinational clinical trial with 'GC1130A', an innovative new drug for Sanfillippo syndrome type A (MPS IIIA). GC Biopharma and Novel Pharma have...

2024-11-26 08:44 1235

Duality Biologics Announces Expansion of Adcendo ApS Collaboration Through Option Exercise of Strategic License Agreement

Adcendo ApS exercises its option to utilize Duality Biologics' platform to further enhance its first-in-class ADC pipeline PRINCETON, N.J., SHANGHAI and SUZHOU, China, Nov. 25, 2024 /PRNewswire/ -- Duality Biologics ("Duality"), a clinical-stage biotech company focusing on the discovery and deve...

2024-11-26 08:30 1115

ReviR Therapeutics and Kennedy's Disease Association Partner to Advance Treatment for Rare Neuromuscular Disorder

BRISBANE, Calif., Nov. 25, 2024 /PRNewswire/ -- ReviR Therapeutics, a pioneering biotechnology company focused on developing novel small molecule RNA modulators for neurogenetic diseases, announced a groundbreaking research grant from the Kennedy's Disease Association (KDA) to advance a therapy f...

2024-11-26 01:00 1188

Cistto Launches the "Humanized Anti-Aging Global Scientist Alliance" in China, Empowering Products with Cutting-Edge Science

LOS ANGELES, Nov. 25, 2024 /PRNewswire/ -- As an emerging brand specializing in sensitive skin repair, Cistto is grounded in skin science and committed to advancing skin health through the latest dermatological breakthroughs and cutting-edge biotechnology. Cistto is steadfast in its promise to de...

2024-11-25 23:00 1526

Food Allergy: LongBio's LP-003 achieves its fourth IND approval

SHANGHAI, Nov. 25, 2024 /PRNewswire/ -- LongBio is proud to announce that the National Medical Products Administration (NMPA,China) has approved the Investigational New Drug (IND) application for LP-003, the company's next-generation anti-IgE antibody, to begin a clinical trial for the treatment ...

2024-11-25 22:00 1249
1 ... 3456789 ... 281